Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catherine Zeta-Jones lawsuit

This article was originally published in The Rose Sheet

Executive Summary

Compaint filed on behalf of actress in Los Angeles federal court against French skin care marketer Caudalie, Neiman Marcus Group and Turnberry Associates claims companies used her name and persona to promote Caudalie products and services without authorization. Zeta-Jones alleges Caudalie and Neiman Marcus featured her name on promotional materials for Caudalie brand products and spas, complaint states. In addition, the Caudalie anti-aging/Vinotherapie Spa at Turnberry Place in Las Vegas unfairly ties its name and services to Zeta-Jones in promotional materials. Zeta-Jones has never used any of the skin care or other products or services provided by Caudalie, according to court document. Actress seeks general and special damages of no less than $5 mil., in addition to punitive and exemplary damages, permanent injunctive relief and expenses...

You may also be interested in...



2020 Could Spell The End Of Mega-Mergers, For Now

Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.

Creating Stability In A Time Of Transition

UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.

Regulatory Measures Could Mitigate EU Coronavirus Risks

As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.

UsernamePublicRestriction

Register

RS011554

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel